Wegovy has a generally favorable safety profile over multiple years of use, though it carries real risks that vary from person to person. The largest long-term trial, SELECT, followed patients for up to five years and found a 20% reduction in major cardiovascular events like heart attacks and strokes. Two-year weight loss data show patients maintained a 15.2% reduction in body weight. But the drug also comes with gastrointestinal side effects, muscle loss concerns, and a few rare but serious complications worth understanding before committing to years of treatment.
Heart Health: The Strongest Safety Signal
The most reassuring long-term data comes from the SELECT trial, which studied semaglutide (Wegovy’s active ingredient) in patients with established cardiovascular disease. Over the course of the trial, participants taking the drug had a 20% lower rate of major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, compared to those on placebo. This isn’t just the absence of harm. It’s an active benefit, and it’s a major reason the FDA expanded Wegovy’s approved uses to include cardiovascular risk reduction in 2024.
For people who carry extra weight and already have heart disease risk factors, this finding shifts the safety conversation significantly. The cardiovascular protection appears to go beyond what weight loss alone would explain, suggesting the drug itself has protective effects on blood vessels and inflammation.
Gastrointestinal Side Effects
The most common complaints with Wegovy are nausea, diarrhea, vomiting, constipation, and abdominal pain. In two-year trial data, 5.9% of patients on Wegovy permanently stopped treatment because of side effects, compared to 4.6% on placebo. That gap is modest, but it reflects only the people who quit entirely. Many more experience GI symptoms that are uncomfortable but tolerable, particularly during the dose escalation period in the first few months.
More concerning are rare but serious gastrointestinal complications. Compared to another weight loss medication (bupropion-naltrexone), GLP-1 drugs like Wegovy were associated with a 3.67 times higher risk of gastroparesis, a condition where the stomach empties too slowly, causing persistent nausea, vomiting, and abdominal pain. They also carried a 4.22 times higher risk of bowel obstruction, which can require surgery. Researchers from the University of British Columbia emphasized that while these events are individually rare, the sheer number of people now taking these drugs means hundreds of thousands could potentially be affected worldwide.
Pancreatitis Risk May Be Lower Than Expected
Early concerns about GLP-1 drugs triggering pancreatitis have not played out the way many expected. A large retrospective study using a global medical database found that semaglutide users actually had lower rates of recurrent acute pancreatitis than non-users: 10.1% versus 27% in one comparison. Even among people with a prior history of pancreatitis, GLP-1 drug users showed significantly fewer repeat episodes. One earlier chart review found that while about 10% of GLP-1 users experienced recurrent pancreatitis, only 4% of those cases were directly linked to the medication itself. The risk hasn’t disappeared, but the data suggest semaglutide doesn’t make pancreatitis worse and may even be protective.
Thyroid Cancer: Animal Risk, Unclear in Humans
Wegovy carries a boxed warning about thyroid C-cell tumors, the most prominent warning a drug label can have. This stems from rodent studies showing increased rates of a rare thyroid cancer called medullary thyroid carcinoma. Whether this translates to humans remains genuinely uncertain. A large Scandinavian cohort study published in The BMJ examined the question but could not confirm an increased risk in people. In the U.S., Wegovy is contraindicated for anyone with a personal or family history of medullary thyroid cancer or a genetic condition called multiple endocrine neoplasia type 2. For everyone else, the warning persists as a precaution based on animal data rather than confirmed human cases.
Muscle Loss During Weight Loss
One of the most important long-term concerns isn’t a traditional “side effect” but a consequence of how the body loses weight. Studies published in The Lancet Diabetes & Endocrinology indicate that 25% to 39% of total weight lost on medications like Wegovy comes from fat-free mass, which includes muscle. If you lose 30 pounds, roughly 8 to 12 of those pounds may be muscle rather than fat.
This matters more the longer you stay on the drug and the more weight you lose. Muscle loss can reduce your metabolic rate, weaken your physical capacity, and increase fall risk, particularly for older adults. Resistance training and adequate protein intake are widely recommended to counteract this effect, though the clinical trials themselves didn’t mandate these interventions. For people planning to use Wegovy for years, protecting muscle should be a deliberate, ongoing priority.
Nutritional Gaps From Eating Less
Wegovy works in part by significantly reducing appetite, which means you eat less food overall. Over months and years, reduced calorie intake can create gaps in vitamins and minerals. A clinical trial currently underway (VITAGLP) is specifically investigating micronutrient deficiencies in long-term GLP-1 users, acknowledging that reduced appetite, altered gut function, and sustained weight loss all increase the risk. While we don’t yet have definitive data on which deficiencies are most common, the biological logic is straightforward: if you’re eating substantially less, you’re absorbing less of everything, including nutrients your body needs.
Bone Health Looks Reassuring
Rapid weight loss from any method, including bariatric surgery, typically increases fracture risk because bones adapt to carrying less load. Wegovy appears to buck this trend. A study comparing semaglutide users to patients who had sleeve gastrectomy found that the semaglutide group had a 26% lower fracture risk over an average follow-up of three years: 2.98% experienced fractures compared to 4.43% in the surgery group. This suggests that the drug may help preserve bone integrity better than surgical weight loss, though longer follow-up will clarify whether this advantage holds over a decade or more.
Mental Health Concerns Have Been Cleared
Early reports raised alarms about a possible link between GLP-1 drugs and suicidal thoughts or behavior. The FDA investigated this thoroughly. Their meta-analysis covered 91 placebo-controlled trials with nearly 108,000 patients and found no increased risk of suicidal ideation, self-harm, depression, anxiety, or psychosis. A separate real-world study using insurance claims data from over 2.2 million patients confirmed the same finding. Based on this evidence, the FDA formally requested that manufacturers remove suicidal behavior warnings from GLP-1 drug labels. This is one safety concern that has been comprehensively investigated and resolved.
Low Blood Sugar if You Have Diabetes
A 2024 update to Wegovy’s prescribing label strengthened warnings about hypoglycemia, specifically for people with type 2 diabetes. In trials of patients with diabetes and a BMI of 27 or higher, 6.2% of Wegovy users experienced blood sugar drops below 54 mg/dL, compared to 2.5% on placebo. The risk is highest for people also taking insulin or sulfonylureas. If you have diabetes and start Wegovy, your other diabetes medications will likely need dose adjustments to prevent dangerous blood sugar lows.
What Long-Term Use Actually Looks Like
Most of Wegovy’s side effects are front-loaded, appearing during the first weeks and months as your body adjusts and the dose increases. The gastrointestinal symptoms typically improve with time, though they don’t vanish for everyone. The more subtle long-term concerns, such as muscle loss, nutritional deficiencies, and the still-uncertain thyroid question, accumulate gradually and won’t announce themselves with obvious symptoms.
Two-year trial data show that the drug continues working: patients maintained significant weight loss at 104 weeks, and the cardiovascular benefits observed in SELECT built over years of follow-up. For many people, particularly those with obesity-related heart disease, the demonstrated benefits likely outweigh the known risks. But “safe” isn’t a binary answer. It depends on your individual health profile, how long you plan to stay on the drug, and whether you’re actively managing the known downsides like muscle preservation and nutrition.